REGULATORY

Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat

July 14, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Yasuhiro Suzuki, who assumed a newly created health ministry post called “imugikan (medical commissioner)” on July 11, sees drug price cuts as the only way to squeeze out budget resources for FY2018, when Japan will have simultaneous revisions of medical…

To read the full story

Suzuki Tapped for Newly Created Medical Commissioner Post: MHLW Personnel Reshuffle
July 5, 2017

REGULATORY

Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…